PT-141 vs Melanotan-2: how they differ
PT-141 (bremelanotide) and Melanotan-2 come up together often because they share a common origin — the melanocortin research program — and because both are associated with sexual arousal. But treating them as interchangeable is a mistake with real consequences. The key difference is not subtle: bremelanotide exists as an approved prescription drug in the U.S. (Vyleesi) for a narrow indication, whereas Melanotan-2 never completed clinical development, is not approved in any country, and carries serious, well-documented safety risks — including mole proliferation and case reports of melanoma. This guide compares the two at an educational level: which receptors they act on, what has been studied for each, what regulators say, and why their safety profiles are not comparable. It is not medical advice and includes no dosing. And an important caveat up front: the fact that bremelanotide has an approved version does not mean the 'research-grade' gray-market material — sold outside pharmacies — is that same product or shares its safeguards.
| PT-141 (Bremelanotide) | Melanotan-2 | |
|---|---|---|
| Target / receptors | More selective melanocortin agonist, acting mainly on MC4R (with some MC3R activity) in the central nervous system. | Non-selective agonist: activates MC1R (skin melanocytes, pigmentation) as well as MC3R/MC4R (central arousal pathways). |
| Effect studied | Sexual desire: approved as Vyleesi in the U.S. for hypoactive sexual desire disorder (HSDD) in premenopausal women. | Pigmentation/tanning (via MC1R) plus effects on sexual arousal; explored in early-stage research, never developed to approval. |
| Regulatory status | Bremelanotide/Vyleesi is an approved prescription drug in the U.S. for a specific indication. | NOT approved for human use in any country (not FDA, EMA or MHRA); sold as a 'research chemical' with public warnings from regulators. |
| Safety profile | Nausea and flushing as the most common effects; transient blood-pressure increases and headache; caution with cardiovascular risk. | Serious risks: darkening/enlargement of moles and melanoma reports in temporal association; priapism (a medical emergency); nausea; diffuse hyperpigmentation. |
| Human evidence | Two randomized, placebo-controlled Phase 3 trials (RECONNECT program) in the approved population. | Almost entirely case reports and case series of adverse events from unsupervised use; no controlled trials establishing benefit. |
| Origin | Synthetic analog developed from the melanocortin program, arousal-oriented, that did reach approval (Vyleesi). | Early-stage research compound from the same program; its more selective analogs (afamelanotide/Scenesse and bremelanotide/Vyleesi) were approved, it was not. |
Same family tree, very different branches
PT-141 and Melanotan-2 come from the same melanocortin research program, which is why they get confused. But the tree branched: Melanotan-2 was an early-stage compound that never completed clinical development, whereas that program eventually produced two more selective, separately approved drugs — afamelanotide (Scenesse), oriented toward pigmentation, and bremelanotide (Vyleesi), oriented toward sexual arousal. PT-141 is precisely the name by which bremelanotide is known as a substance. Put differently: Melanotan-2 is the older, non-selective relative that was left out of approval, and PT-141/bremelanotide is the branch that did pass clinical trials for a specific indication. Sharing an origin does not make them equivalent in how they act or how safe they are.
Receptor selectivity: why Melanotan-2 affects the skin
The underlying mechanistic difference is selectivity. Bremelanotide (PT-141) acts more selectively on the MC4R receptor in the central nervous system — the pathway linked to sexual desire — with some MC3R activity. Melanotan-2, by contrast, is a non-selective agonist: on top of MC3R/MC4R, it strongly activates MC1R, the melanocyte receptor in the skin that drives melanin production. That lack of selectivity is why Melanotan-2 was used as a 'tanning injection', and also the root of its most serious safety problem: by sustainedly stimulating melanocytes, it is associated with the darkening and growth of moles, the appearance of new atypical nevi, and diffuse skin hyperpigmentation. PT-141, with its more central and selective action, does not share that cutaneous mechanism. Selectivity is not a technicality: it is the line that separates a bounded effect from a diffuse one with dermatological consequences.
Safety: Melanotan-2 is not a cheaper PT-141
This is the point to stress most firmly, because in forums they are sometimes presented as interchangeable options and they are not. Bremelanotide's profile in its trials centers on nausea, flushing, transient blood-pressure increases and headache, with a caution flag for people with cardiovascular risk factors. Melanotan-2's is of another category: documented risks include the darkening, enlargement and appearance of atypical moles, with published case reports of melanoma arising in temporal association with its use; priapism (a prolonged, painful erection that is a medical emergency); nausea and facial flushing; diffuse hyperpigmentation; and rare reports of systemic toxicity and rhabdomyolysis after overdose. Anyone with a personal or family history of melanoma or of atypical/dysplastic moles should treat Melanotan-2 with particular caution and seek dermatologic evaluation for any new or changing mole. A third-party CoA confirming what is in a vial does nothing to mitigate these inherent biological risks: Melanotan-2's problem is not just material quality, but the compound itself.
Approved is not the same as gray-market material
The regulatory distinction is clear on paper and should not be blurred. Bremelanotide is FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women, based on two placebo-controlled Phase 3 trials; Melanotan-2 is not approved by any medicines regulator — not the FDA, EMA or MHRA — and several bodies have issued public warnings against its use. That said, there is a nuance no honest comparison should omit: the existence of Vyleesi does not turn the 'research-grade' PT-141 sold outside pharmacies into an approved product. That gray-market material is not the same regulated product; it does not carry a prescriber's oversight, dose control or the quality assurance of the pharmacy route, and it is not intended for human use. Approval attaches to a specific product, via a specific route, for a specific indication — not to the molecule in the abstract, nor to any vial that bears the name. In short: PT-141 has an approved version and Melanotan-2 has none, but even PT-141 obtained outside a pharmacy does not inherit that approval.
Frequently asked questions
- What is the main difference between PT-141 and Melanotan-2?
- Selectivity, regulatory status and safety. PT-141 (bremelanotide) is more selective for MC4R, is studied for sexual desire, and exists as an approved prescription drug in the U.S. (Vyleesi). Melanotan-2 is a non-selective agonist that also activates skin MC1R (hence the tanning), is not approved in any country, and carries serious risks such as mole proliferation and melanoma reports. They are not interchangeable. This answer is educational, not medical advice.
- If PT-141 is approved (Vyleesi), is it safe to buy it as a 'research peptide'?
- Not in the same way. Approval belongs to a specific product (Vyleesi), by prescription and for a specific indication. The 'research-grade' material sold outside pharmacies is not that regulated product: it carries no prescriber oversight, dose control or quality assurance, and is not intended for human use. The molecule having an approved version does not transfer that approval to a gray-market vial. Educational information, not medical advice.
- Why is Melanotan-2 considered riskier?
- Because its lack of selectivity strongly stimulates the skin's melanocytes (MC1R), and that is associated with the darkening and growth of moles, the appearance of new atypical nevi, and published melanoma reports in temporal association with its use, plus priapism (a medical emergency). It is not approved by any regulator. Anyone with a personal or family history of melanoma or atypical moles should be especially cautious and seek dermatologic evaluation for any new or changing mole. This information is educational.
✓ Last reviewed · 2026-07-24